You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.
Newly launched aggregator Seqster will help Boston University researchers collect data from EHRs, wearables, and gene tests to identify concussion biomarkers.
The partners have formed a public/private partnership to foster collaboration and data integration between different institutes researching brain trauma.
The firm wants to develop a test that can provide objective, reliable, and rapid information so that clinicians can make critical decisions in circumstances of high uncertainty.
The company will develop the assays for its single-molecule array technology and incorporate the markers into multiplex assays for research use in neurology.
The firm is investing in studies that use its multiplex microarray platform to monitor lupus disease activity and traumatic brain injury response.
The firm will look for metabolic profiles that could help diagnose asphyxia in human newborns, signatures that were derived from animal studies.
The firms said their test will be developed to detect levels of the tau protein that can leak into a person's bloodstream after head trauma or injury.
The grant is being provided under the NIH's Extracellular RNA Communication program, which was set up to study the role of molecules such as microRNAs.
Researchers sequenced the genome of Spirometra erinaceieuropaei with DNA from tapeworm that had been living in the patient's brain for several years.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.